Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.

Frédéric Schmidt (1)

1 CBMCT - UMR 3666 / U1143 - Chimie biologique des membranes et ciblage thérapeutique

New prodrugs consisting of a beta-D-glucuronic acid linked to a MDR reversal agent (verapamil, quinine or dipyridamole) through a self-immolative spacer were synthesized. Four of them were selected for their reduced cytoxicity and beta-glucuronidase enzymatic efficient hydrolysis. Combined use of these prodrugs with a beta-D-glucuronyl-spacer-doxorubicin (HMR1826) according to an ADEPT strategy restored in vitro the sensibility of a MDR resistant strain.

Domaines: Chimie; Sciences du Vivant [q-bio]

Frédéric Schmidt. Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.. Anti-Cancer Drug Design, 1999, 14 (2), pp.93-106. ⟨hal-02137891⟩